Table 2.

Mean changes from baseline to end point in total IPSS, IPSS subscores, IPSS quality of life index, and maximum flow rate in 12-week, double-blind, randomized, placebo-controlled clinical studies of tamsulosin in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Study	Treatment	n	Mean change from baseline
			Total IPSS	IPSS storage subscore	IPSS voiding subscore	IPSS QoL index	Qmax, ml/s
Asian studies$
Yokoyama et al. [2013]	Placebo	154	−3.0	−1.1	−1.9	−0.5	2.1
	Tadalafil 5 mg	155	−4.7*	−1.7*	−3.0*	−0.8*	1.3
	Tamsulosin 0.2 mg	152	−5.5	−1.7	−3.8	−1.1	2.1
Kawabe et al. [2006]	Placebo	89	−5.3	−1.5	−3.8	−1.1	0.3
	Tamsulosin 0.2 mg	192	−6.8	−2.1	−4.8	−1.4	2.6
Kim et al. [2011]	Placebo	51	−4.2	−1.5	−2.7	−0.9	2.3
	Tadalafil 5 mg	51	−5.8	−2.1	−3.7	−1.2	2.5
	Tamsulosin 0.2 mg	49	−5.4	−1.8	−3.6	−1.0	2.1
Non-Asian study
Oelke et al. [2012]	Placebo	172	−4.2	−1.6	−2.6	−1.0	1.2
	Tadalafil 5 mg	171	−6.3*	−2.2	−4.1*	−1.3*	2.4*
	Tamsulosin 0.4 mg	168	−5.7*	−2.2	−3.5*	−1.1	2.2*

^*p < 0.05 versus placebo.

^$Tamsulosin versus placebo statistical comparisons were not made in the studies reported by Kawabe et al. [2006] and Yokoyama et al. [2013].

IPSS, International Prostate Symptom Score; n, number of randomized participants; Q_max, maximum urinary flow rate; QoL, quality of life.